178 related articles for article (PubMed ID: 33819964)
1. [Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer].
Ni J; Huang M; Zhang L; Wu N; Bai C; Chen L; Liang J; Liu Q; Wang J; Wu Y; Zhang F; Zhang S; Chen C; Chen J; Fang W; Gao S; Hu J; Jiang T; Li S; Li H; Liao Y; Liu Y; Liu D; Liu H; Liu J; Liu L; Wang M; Wang C; Yang F; Yang Y; Zhang L; Zhi X; Zhong W; Guan Y; Guo X; He C; Li S; Li Y; Liang N; Lu F; Lv C; Lv W; Si X; Tan F; Wang H; Wang J; Yan S; Yang H; Zhu H; Zhuang J; Zhuo M
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):141-160. PubMed ID: 33819964
[TBL] [Abstract][Full Text] [Related]
2. Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer.
Ni J; Huang M; Zhang L; Wu N; Bai CX; Chen LA; Liang J; Liu Q; Wang J; Wu YL; Zhang FC; Zhang SY; Chen C; Chen J; Fang WT; Gao SG; Hu J; Jiang T; Li SQ; Li HC; Liao YD; Liu Y; Liu DR; Liu HX; Liu JY; Liu LX; Wang MZ; Wang CL; Yang F; Yang Y; Zhang LJ; Zhi XY; Zhong WZ; Guan YZ; Guo XX; He CX; Li SL; Li Y; Liang NX; Lu FL; Lv C; Lv W; Si XY; Tan FW; Wang HP; Wang JS; Yan S; Yang HX; Zhu HJ; Zhuang JL; Zhuo ML
Thorac Cancer; 2021 May; 12(9):1469-1488. PubMed ID: 33787090
[TBL] [Abstract][Full Text] [Related]
3. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study.
Kobayashi T; Iwama S; Yasuda Y; Okada N; Okuji T; Ito M; Onoue T; Goto M; Sugiyama M; Tsunekawa T; Takagi H; Hagiwara D; Ito Y; Suga H; Banno R; Yokota K; Hase T; Morise M; Hashimoto N; Ando M; Fujimoto Y; Hibi H; Sone M; Ando Y; Akiyama M; Hasegawa Y; Arima H
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32606047
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M
Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270
[TBL] [Abstract][Full Text] [Related]
5. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
[TBL] [Abstract][Full Text] [Related]
6. Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors.
Hsiehchen D; Watters MK; Lu R; Xie Y; Gerber DE
JAMA Netw Open; 2019 Sep; 2(9):e1911519. PubMed ID: 31532516
[TBL] [Abstract][Full Text] [Related]
7. Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy.
Abed A; Law N; Calapre L; Lo J; Bhat V; Bowyer S; Millward M; Gray ES
Eur J Cancer; 2022 Sep; 172():98-106. PubMed ID: 35759816
[TBL] [Abstract][Full Text] [Related]
8. Impact of Neoadjuvant Immune Checkpoint Inhibitors on Surgery and Perioperative Complications in Patients With Non-small-cell Lung Cancer: A Systematic Review.
Takada K; Takamori S; Brunetti L; Crucitti P; Cortellini A
Clin Lung Cancer; 2023 Nov; 24(7):581-590.e5. PubMed ID: 37741717
[TBL] [Abstract][Full Text] [Related]
9. Association between immune-related adverse event timing and treatment outcomes.
Hsiehchen D; Naqash AR; Espinoza M; Von Itzstein MS; Cortellini A; Ricciuti B; Owen DH; Laharwal M; Toi Y; Burke M; Xie Y; Gerber DE
Oncoimmunology; 2022; 11(1):2017162. PubMed ID: 35003896
[TBL] [Abstract][Full Text] [Related]
10. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
[TBL] [Abstract][Full Text] [Related]
11. Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors.
Lu S; Yu Y; Yang Y
Oncologist; 2019 Feb; 24(Suppl 1):S21-S30. PubMed ID: 30819828
[TBL] [Abstract][Full Text] [Related]
12. Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma.
Chen M; Ma P; Zhang Y; Wang D; Yu Z; Fu Y; Zhao X; Wang M; Zhuang G; Jing Y
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857527
[TBL] [Abstract][Full Text] [Related]
13. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
15. [Progress of immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer].
Chen XY; Yang F
Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):872-877. PubMed ID: 31694138
[TBL] [Abstract][Full Text] [Related]
16. Opportunistic infections complicating immunotherapy for non-small cell lung cancer.
Liu Z; Liu T; Zhang X; Si X; Wang H; Zhang J; Huang H; Sun X; Wang J; Wang M; Zhang L
Thorac Cancer; 2020 Jun; 11(6):1689-1694. PubMed ID: 32311221
[TBL] [Abstract][Full Text] [Related]
17. [Developments in Immunotherapy for Advanced Non-small Cell Lung Cancer].
Li H; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Feb; 24(2):131-140. PubMed ID: 33508897
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer.
Issa M; Tang J; Guo Y; Coss C; Mace TA; Bischof J; Phelps M; Presley CJ; Owen DH
Expert Rev Anticancer Ther; 2022 Aug; 22(8):861-874. PubMed ID: 35786142
[TBL] [Abstract][Full Text] [Related]
19. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Zhang M; Rodrigues AJ; Pollom EL; Gibbs IC; Soltys SG; Hancock SL; Neal JW; Padda SK; Ramchandran KJ; Wakelee HA; Chang SD; Lim M; Hayden Gephart M; Li G
J Neurooncol; 2021 Mar; 152(1):125-134. PubMed ID: 33415659
[TBL] [Abstract][Full Text] [Related]
20. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
Leonardi GC; Gainor JF; Altan M; Kravets S; Dahlberg SE; Gedmintas L; Azimi R; Rizvi H; Riess JW; Hellmann MD; Awad MM
J Clin Oncol; 2018 Jul; 36(19):1905-1912. PubMed ID: 29746230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
